Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Javanese cinnamon bark (Cinnamomum burmannii) is a cassia-type cinnamon whose essential oil contains 73–76% trans-cinnamaldehyde along with procyanidin type-A polymers, which inhibit IKKβ kinase–mediated NF-κB activation to suppress inflammatory mediators COX-2, iNOS, TNF-α, and IL-6 while enhancing insulin-receptor signaling and GLUT4 translocation. Randomized controlled trials of cassia-type cinnamon supplementation (1–6 g/day for 40–120 days) have reported 18–29% reductions in fasting blood glucose and statistically significant improvements in HbA1c, serum triglycerides, and LDL cholesterol in type 2 diabetes cohorts.
Reported Benefits (Provisional)
Origin & History
Javanese Cinnamon Bark (Cinnamomum burmannii) is derived from trees native to Indonesia, particularly the islands of Java and Sumatra, thriving in warm, tropical climates and fertile volcanic soils. This aromatic bark is prized for its unique flavor and potent bioactive compounds, offering significant benefits for metabolic and cardiovascular health.
Research Narrative (Provisional)
Multiple randomized controlled trials evaluating cassia-type cinnamon barks, including Cinnamomum burmannii, have demonstrated that daily supplementation of 1–6 g for 40–120 days produces 18–29% reductions in fasting blood glucose, with statistically significant improvements in HbA1c, serum triglycerides, and LDL cholesterol in type 2 diabetes cohorts. In vitro mechanistic studies confirm that trans-cinnamaldehyde and procyanidin type-A polymers extracted from C. burmannii inhibit IKKβ kinase activity and downstream NF-κB nuclear translocation, suppressing expression of COX-2, iNOS, TNF-α, and IL-6. Systematic reviews and meta-analyses of cinnamon supplementation trials, as summarized by the National Center for Complementary and Integrative Health (NCCIH), note that while results are promising, variability in species identification, dosing protocols, and study duration complicates definitive clinical conclusions. Additional research using standardized C. burmannii extracts with verified trans-cinnamaldehyde and coumarin content is needed to establish species-specific efficacy and safety profiles.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Minerals: Manganese, Calcium, Potassium, Magnesium. - Phytochemicals & Bioactives: Cinnamaldehyde, Eugenol, Polyphenols, Flavonoids, Proanthocyanidins, Plant sterols, Coumarins. - Other: Prebiotic fiber.
Reported Mechanism (Provisional)
Trans-cinnamaldehyde, comprising 73–76% of C. burmannii essential oil, competitively occupies the ATP-binding pocket of IKKβ kinase (inhibitor of nuclear factor kappa-B kinase subunit beta), preventing phosphorylation and subsequent proteasomal degradation of IκBα and thereby blocking NF-κB nuclear translocation and transcription of pro-inflammatory genes including COX-2, iNOS, TNF-α, and IL-6. Procyanidin type-A polymers present in the aqueous extract activate insulin receptor substrate-1 (IRS-1) phosphorylation and enhance PI3K/Akt signaling, promoting GLUT4 transporter translocation to the cell membrane and improving peripheral glucose uptake independent of insulin secretion. These procyanidins also inhibit intestinal α-glucosidase and pancreatic α-amylase activity, delaying carbohydrate digestion and attenuating postprandial glycemic spikes. Additionally, trans-cinnamaldehyde activates TRPA1 channels and Nrf2-mediated antioxidant response element (ARE) pathways, upregulating phase II detoxification enzymes such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1).
Clinical Narrative (Provisional)
Current evidence relies primarily on preclinical and in vitro studies, with no published randomized controlled trials for Cinnamomum burmannii specifically. Laboratory studies show ethanol extracts contain 36.67 mg GAE/g total phenolics with free radical scavenging capacity of 1688.85 μmol TE/g against hydroxyl radicals. Water extracts demonstrate lower but significant activity at 583.12 μmol TE/g. Human clinical trials are needed to establish therapeutic dosing and efficacy parameters.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.